Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer's disease ... including amyloid beta, tau, ...
A new interdisciplinary study at the University of Delaware seeks to study AD by examining changes in the arteries and brain ...
Johns Hopkins University-led researchers, working with the Biomarkers for Older Controls at Risk for Dementia (BIOCARD) ...
And also we found the significant effects in terms of ADAS-Cog [Alzheimer's Disease Assessment Scale-Cognitive Subscale], ...
Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...
Prothena is evaluating PRX012 — a wholly owned investigational next-generation subcutaneous, single-injection once-monthly antibody delivered subcutaneously targeting a key epitope at the N-terminus ...
Acumen Pharmaceuticals, Inc. ( (ABOS) ) has released its Q3 earnings. Here is a breakdown of the information Acumen Pharmaceuticals, Inc.
Alongside beta-amyloid, the second major target of drugs in development for Alzheimer's is the tau protein, responsible for ...
Alzheimer's disease is the most common cause of dementia in the elderly and is characterized by abnormal deposits of amyloid-beta and tau proteins in the brain. This disease has a ...
protects memory and learning ability and reduces the formation of amyloid-beta plaques and neurofibrillary tangles (classic ...
This focus could potentially offer a more effective and safer treatment for Alzheimer’s, addressing a critical need ... is a subclass monoclonal antibody which selectively targets amyloid-beta ...